Ixekizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ixekizumab: From Psoriasis and Spondyloarthritis to Rheumatoid Vasculitis
One-Sentence Summary
Ixekizumab is an IL-17A-blocking monoclonal antibody, marketed as TALTZ and used for psoriasis, psoriatic arthritis and axial spondyloarthritis. The TxGNN model predicts it may be effective for rheumatoid vasculitis, but no ixekizumab-specific trial or publication supports this yet. The one linked trial studies perioperative immunosuppressant management, not ixekizumab efficacy.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis / axial spondyloarthritis (taken from the literature and trial data; the approved-indication text was not supplied in the license records) |
| Predicted New Indication | Rheumatoid vasculitis |
| TxGNN Prediction Score | 97.53% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 4 (all listings under BLA125521) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data from DrugBank is not available. Ixekizumab is a selective IL-17A antagonist. IL-17A drives inflammation in psoriasis, psoriatic arthritis and axial spondyloarthritis, and Phase 3 trials have confirmed efficacy in those diseases.
IL-17A has also been implicated in autoimmune vasculitis, so a link to rheumatoid vasculitis is plausible in principle. However, no ixekizumab-specific efficacy data exist for this condition. The high score (0.975) is a graph-based prediction and should not be read as clinical evidence.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Compares shorter vs longer preoperative immunosuppressant holds in rheumatology patients having shoulder arthroplasty. It does not test ixekizumab for rheumatoid vasculitis, so it provides no efficacy evidence (relevance grade C). |
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125521 (4 listings) | TALTZ (Eli Lilly and Company) | Injection, solution | Indication text not included in the supplied records |
Safety Considerations
The pack contains no package-insert warnings or contraindications, and the drug-interaction query returned no results. Please refer to the package insert for safety information.
Class-level cautions from the literature attached to other predicted indications:
- Inflammatory bowel disease: IL-17 blockers can trigger new-onset or worsening IBD (PMID 32719044).
- Infections and vaccination: check infection and vaccination status before and during therapy (PMID 38331098).
- Immunosuppression: a theoretical concern in any additional immune-mediated or malignant setting.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. No trial or publication tests ixekizumab in rheumatoid vasculitis, and the single linked trial is unrelated to efficacy.
Other predicted indications:
- Inflammatory spondylopathy and vertebral disease (ranks 6 and 9) have L1 evidence and are rated “Proceed with Guardrails”. This comes from multiple completed Phase 3 RCTs in psoriatic arthritis and axial spondyloarthritis (for example COAST-V, COAST-X, SPIRIT-P1 and SPIRIT-P2). These correspond to already-labeled uses, so they are on-label confirmation, not novel repurposing.
- Haematologic malignancies (ALL and CLL/SLL), coccyx hypermobility, Kummell disease and gingival fibromatosis have no supporting evidence and no plausible IL-17A mechanism.
- Polyarticular juvenile rheumatoid arthritis is plausible in principle but has no linked trial or publication.
To proceed, the following is needed:
- Any preclinical, case-series or trial evidence of IL-17A blockade in rheumatoid vasculitis
- Approved-indication text and package-insert warnings and contraindications (label data are missing from the pack)
- DrugBank mechanism-of-action data
- Correction of the empty original-indication field so on-label uses are not mistaken for new repurposing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.